遗传、生物学和药理学因素对帕金森病左旋多巴剂量的影响。
Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
作者信息
Altmann Vivian, Schumacher-Schuh Artur F, Rieck Mariana, Callegari-Jacques Sidia M, Rieder Carlos R M, Hutz Mara H
机构信息
Departamento de Genética, Instituto de Biociências, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Serviço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
出版信息
Pharmacogenomics. 2016 Apr;17(5):481-8. doi: 10.2217/pgs.15.183. Epub 2016 Mar 29.
AIM
Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors.
PATIENTS & METHODS: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed.
RESULTS
All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001).
CONCLUSION
Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.
目的
左旋多巴是帕金森病运动症状的一线治疗药物，但剂量反应差异很大。因此，本研究的目的是确定生物、药理和遗传因素能在多大程度上解释左旋多巴的剂量。
患者与方法
通过等位基因鉴别分析对总共224例帕金森病患者的SV2C和SLC6A3基因多态性进行基因分型。同时评估合并用药、人口统计学和临床数据。
结果
所有p<0.20的变量都纳入剂量预测的多元回归分析。最终模型解释了23%的剂量变异（F=11.54；p<0.000001）。
结论
虽然获得了一个良好的预测模型，但仍需在独立样本中进行测试以验证其有效性。
Zotero 插件